Conceived and designed the experiments: HMT WM JDK RMG. Performed the experiments: HMT BL. Analyzed the data: HMT TAK WM RMG. Contributed reagents/materials/analysis tools: JDK SSP RMG. Wrote the paper: HMT TAK WM.
The authors have declared that no competing interests exist.
HIV-1 acute infection, recent infection and transmitted drug resistance screening was integrated into voluntary HIV counseling and testing (VCT) services to enhance the existing surveillance program in San Francisco. This study describes newly-diagnosed HIV cases and characterizes correlates associated with infection.
A consecutive sample of persons presenting for HIV VCT at the municipal sexually transmitted infections (STI) clinic from 2004 to 2006 (N = 9,868) were evaluated by standard enzyme-linked immunoassays (EIA). HIV antibody-positive specimens were characterized as recent infections using a less-sensitive EIA. HIV-RNA pooled testing was performed on HIV antibody-negative specimens to identify acute infections. HIV antibody-positive and acute infection specimens were evaluated for drug resistance by sequence analysis. Multivariable logistic regression was performed to evaluate associations. The 380 newly-diagnosed HIV cases included 29 acute infections, 128 recent infections, and 47 drug-resistant cases, with no significant increases or decreases in prevalence over the three years studied. HIV-1 transmitted drug resistance prevalence was 11.0% in 2004, 13.4% in 2005 and 14.9% in 2006 (p = 0.36). Resistance to non-nucleoside reverse transcriptase inhibitors (NNRTI) was the most common pattern detected, present in 28 cases of resistance (59.6%). Among MSM, recent infection was associated with amphetamine use (AOR = 2.67; p<0.001), unprotected anal intercourse (AOR = 2.27; p<0.001), sex with a known HIV-infected partner (AOR = 1.64; p = 0.02), and history of gonorrhea (AOR = 1.62; p = 0.03).
New HIV diagnoses, recent infections, acute infections and transmitted drug resistance prevalence remained stable between 2004 and 2006. Resistance to NNRTI comprised more than half of the drug-resistant cases, a worrisome finding given its role as the backbone of first-line antiretroviral therapy in San Francisco as well as worldwide. The integration of HIV-1 drug resistance, recent infection, and acute infection testing should be considered for existing HIV/STI surveillance and prevention activities, particularly in an era of enhanced efforts for early diagnosis and treatment.
HIV-1 acute infection, recent infection and antiretroviral (ARV) drug resistance are of clinical and public health significance. Acute infection is defined as the time interval between the acquisition of HIV infection and seroconversion. The high viral load during this stage of infection increases biological transmissibility
Sexually transmitted infections (STI) clinic patients are a sentinel population used for HIV surveillance worldwide based on the rationale that high numbers of persons newly infected with HIV may first present at such facilities since the behaviors that place individuals at risk for acquiring STI and HIV are similar
The study received approval from the Institutional Review Board at the University of California, San Francisco. No additional data were collected for this public health surveillance activity; therefore, written patient consent was not required.
A consecutive sample of persons presenting for confidential HIV VCT at the San Francisco municipal STI clinic from January 2004 to December 2006 (N = 9,868) were evaluated. Newly-identified HIV cases were considered to be ARV treatment-naïve since the study population was comprised of testers seeking to know their HIV status.
Specimens were screened using standard enzyme-linked immunoassays (EIA) (Vironostika HIV-1 Microelisa, bioMérieux, Durham, NC) and OraQuick Rapid Test (OraQuick Advance HIV 1/2 Antibody Test, Bethlehem, PA). Antibody-positive samples were confirmed using immunofluoresence assays (Fluorognost HIV-1 IFA, Sanochemia Pharmazeutika AG, Neufeld, Vienna, Austria). HIV Ab+ specimens were characterized as recent HIV infections using a testing approach referred to as “STARHS”, which stands for “Serological Testing Algorithm for Recent HIV Seroconversion”. STARHS distinguishes recent from long-term infections using two EIA: a standard assay (Vironostika HIV-1) that is sensitive to low levels of HIV antibody and a less-sensitive one (Vironostika-LS) that classifies recent infection using a 170 day window period [95% CI: 145, 200 days] and an optical density cut-off value of 1.0
Newly-detected HIV infections (RNA+/Ab+ and RNA+/Ab−) were evaluated for drug resistance by viral genotype population sequencing (TRUGENE HIV-1 Genotyping Kit, Bayer Diagnostics, Emeryville, CA). The assay detects mutations in the protease and reverse transcriptase sequences of the HIV-1 genome that confer resistance to ARVs. Viral genotypic sequencing was performed on 370 HIV+ specimens and interpretable sequences were generated for 348 specimens, yielding a 94% assay success rate. Sequencing results were interpreted using guidelines from the manufacturer (Version 12 Rules), IAS-USA, and the Stanford University HIV-1 Drug Resistance Surveillance Program
Demographic characteristics and risk behavior information were obtained from standardized intake data collection forms that were administered by test counselors in private settings as a routine part of HIV VCT services. Correlates of acute and recent HIV infection and transmitted drug resistance were based on secondary analysis of existing data. Data available for analysis included demographic characteristics (e.g., gender, age, racial/ethnic identification, sexual orientation), sexual behavior (e.g., gender of sex partners, number of sex partners, engaging in unprotected sexual intercourse, and sex with a known HIV-infected partner within the past twelve months), substance use (e.g., use of injection drugs, non-injection drugs, and alcohol within the past twelve months), and medical history (e.g., perceived HIV status before the current test, number of previous HIV tests, and STD history within the past two years).
HIV infection, recent infection, acute infection, and drug resistance were compared across years. HIV infection cases included all persons who were either antibody positive by standard antibody testing or who were acutely infected. Stages of HIV infection were defined as follows: (i) acute infections were RNA+/Ab−, (ii) recent infections were RNA+/Ab+ and transmission likely occurred within the past 170 days, and (iii) long-term infections were RNA+/Ab+ and transmission likely occurred beyond the past 170 days. HIV-1 drug resistance was defined as having a single major mutation or several minor mutations known to confer intermediate or high levels of resistance to ARVs. HIV-1 incidence estimates were calculated by dividing the number of persons with recent infection by persons at risk (recently infected plus uninfected) and annualized using the following formula: crude incidence x [(365 days/170 days) x 100%]
The HIV VCT population consisted of 3,789 testers in 2004, 2,921 testers in 2005, and 3,158 testers in 2006. Testers were 84.4% male, 14.1% female, and 1.3% transgender. By age, 18.1% were under 25 years old, 41.1% were 25–34, 27.6% were 35–44, and 13.0% were 45 and older. The testing population was comprised of 54.4% whites, 20.0% Latinos, 10.6% African-Americans, 11.8% Asian/Pacific Islanders, and 3.0% other/mixed race. Risk exposure data were available for 93.8% of testers (n = 9,380), of which 73.1% were men who have sex with men (MSM), 23.6% were heterosexual, 1.9% were injection drug users (IDU), and 1.4% were transgender. Among all testers, 36.2% reported unprotected anal sex (UAI), 16.9% had sex with a known HIV-positive partner, 11.7% used amphetamines, 4.1% used injection drugs, 14.7% had a history of gonorrhea, 9.5% had a history Chlamydia, and 3.2% had a history of syphilis.
There were 380 HIV infections newly diagnosed between 2004 and 2006. Newly-identified HIV cases comprised of 223 long-term infections (58.7%), 128 recent infections (33.7%), and 29 acute infections (7.6%). Eleven of the 29 acute infection specimens were originally screened by the rapid test.
All Testers | HIV-Negative | All HIV Infection | Long-Term Infection | Recent Infection | Acute Infection | HIV-1 Drug Resistance | ||||||||||
N = 9,868 | N = 9,488 | N = 380 | N = 223 | N = 128 | N = 29 | Genotyped N = 362 | Drug-Resistant Cases N = 47 | |||||||||
n | % |
n | % |
HIV Prevalence % [95% CI] |
n | % |
n | % |
HIV Incidence % [95% CI] | n | % |
n | n | % |
||
|
||||||||||||||||
2004 | 3,789 | 3,653 | 38.5 | 136 | 35.8 | 3.59 [3.48, 4.25] | 81 | 36.3 | 44 | 34.4 | 2.55 [1.81, 3.35] | 11 | 37.9 | 136 | 15 | 31.9 |
2005 | 2,921 | 2,794 | 29.4 | 127 | 33.4 | 4.35 [3.64, 5.15] | 73 | 32.7 | 44 | 34.4 | 3.32 [2.35, 4.34] | 10 | 34.5 | 112 | 15 | 31.9 |
2006 | 3,158 | 3,041 | 32.1 | 117 | 30.8 | 3.70 [3.07, 4.42] | 69 | 30.9 | 40 | 31.3 | 2.78 [1.94, 3.71] | 8 | 27.6 | 114 | 17 | 36.2 |
|
||||||||||||||||
Men | 8,332 | 7,970 | 84.0 | 362 | 95.3 | 4.34 [3.92, 4.80] | 210 | 94.2 | 125 | 97.7 | 3.31 [2.68, 3.84] | 27 | 93.1 | 345 | 41 | 87.2 |
Women | 1,396 | 1,387 | 14.6 | 9 | 2.4 | 0.64 [0.30, 1.22] | 7 | 3.1 | 2 | 1.6 | 0.31 [0.04, 1.11] | 0 | 0.0 | 8 | 2 | 4.3 |
Transgender | 128 | 123 | 1.3 | 5 | 1.3 | 3.91 [1.28, 8.88] | 4 | 1.8 | 1 | 0.8 | 1.73 [0.04, 9.35] | 0 | 0.0 | 5 | 1 | 2.1 |
Missing | 12 | 8 | 0.1 | 4 | 1.1 | 33.33 [9.92, 65.11] | 2 | 0.9 | 0 | 0.0 | 0.00 [0.00, 66.05] | 2 | 6.9 | 4 | 3 | 6.4 |
|
||||||||||||||||
Under 25 | 1,789 | 1,742 | 18.4 | 47 | 12.4 | 2.63 [1.94, 3.48] | 17 | 7.6 | 25 | 19.5 | 3.03 [1.94, 4.43] | 5 | 17.2 | 45 | 5 | 10.6 |
25–34 | 4,059 | 3,919 | 41.3 | 140 | 36.8 | 3.45 [2.91, 4.06] | 83 | 37.2 | 48 | 37.5 | 2.59 [1.87, 3.37] | 9 | 31.0 | 137 | 16 | 34.0 |
35–44 | 2,719 | 2,589 | 27.3 | 130 | 34.2 | 4.78 [4.01, 5.65] | 80 | 35.9 | 40 | 31.3 | 3.26 [2.26, 4.30] | 10 | 34.5 | 124 | 17 | 36.2 |
45 and older | 1,284 | 1,226 | 12.9 | 58 | 15.3 | 4.52 [3.45, 5.80] | 40 | 17.9 | 15 | 11.7 | 2.59 [1.40, 4.14] | 3 | 10.3 | 51 | 6 | 12.8 |
Missing | 17 | 12 | 0.1 | 5 | 1.3 | 29.41 [10.31, 55.96] | 3 | 1.3 | 0 | 0.0 | 0.00 [0.00, 46.62] | 2 | 6.9 | 5 | 3 | 6.4 |
|
||||||||||||||||
White | 5,359 | 5,181 | 54.6 | 178 | 46.8 | 3.32 [2.86, 3.84] | 96 | 43.0 | 69 | 53.9 | 2.82 [2.15, 3.50] | 13 | 44.8 | 173 | 20 | 42.6 |
Latino | 1,968 | 1,874 | 19.8 | 94 | 24.7 | 4.78 [3.88, 5.81] | 57 | 25.6 | 30 | 23.4 | 3.37 [2.21, 4.68] | 7 | 24.1 | 91 | 10 | 21.3 |
African-American | 1,042 | 991 | 10.4 | 51 | 13.4 | 4.89 [3.67, 6.39] | 29 | 13.0 | 19 | 14.8 | 4.03 [2.36, 6.12] | 3 | 10.3 | 49 | 8 | 17.0 |
Asian/Pacific Islander | 1,162 | 1,138 | 12.0 | 24 | 6.3 | 2.07 [1.33, 3.06] | 16 | 7.2 | 6 | 4.7 | 1.12 [0.41, 2.41] | 2 | 6.9 | 22 | 4 | 8.5 |
Other/Mixed | 293 | 270 | 2.8 | 23 | 6.1 | 7.85 [5.04, 11.55] | 17 | 7.6 | 4 | 3.1 | 3.11 [0.80, 7.51] | 2 | 6.9 | 19 | 1 | 2.1 |
Missing | 44 | 34 | 0.4 | 10 | 2.6 | 22.73 [11.47, 37.84] | 8 | 3.6 | 0 | 0.0 | 0.00 [0.00, 18.01] | 2 | 6.9 | 8 | 4 | 8.5 |
|
||||||||||||||||
MSM | 6,859 | 6,531 | 68.8 | 328 | 86.3 | 4.78 [4.29, 5.31] | 191 | 85.7 | 110 | 85.9 | 3.54 [2.83, 4.15] | 27 | 93.1 | 315 | 36 | 76.6 |
Heterosexual | 2,212 | 2,196 | 23.1 | 16 | 4.2 | 0.72 [0.41, 1.17] | 11 | 4.9 | 5 | 3.9 | 0.49 [0.16, 1.13] | 0 | 0.0 | 15 | 5 | 10.6 |
IDU (non-MSM) | 177 | 172 | 1.8 | 5 | 1.3 | 2.82 [0.92, 6.47] | 1 | 0.4 | 2 | 1.6 | 2.44 [0.29, 8.77] | 0 | 0.0 | 3 | 0 | 0.0 |
Transgender | 132 | 129 | 1.4 | 3 | 0.8 | 2.27 [0.47, 6.50] | 2 | 0.9 | 1 | 0.8 | 1.65 [0.04, 9.07] | 0 | 0.0 | 3 | 1 | 2.1 |
Missing | 488 | 458 | 4.8 | 30 | 7.9 | 6.15 [4.19, 8.66] | 18 | 8.1 | 10 | 7.8 | 4.57 [2.11, 8.10] | 2 | 6.9 | 26 | 5 | 10.6 |
|
||||||||||||||||
Sex with Known HIV+ Partner | 1,668 | 1,532 | 16.1 | 136 | 35.8 | 8.15 [6.88, 9.57] | 75 | 33.6 | 53 | 41.4 | 7.15 [5.11, 8.93] | 8 | 27.6 | 114 | 13 | 27.7 |
Unprotected Anal Intercourse | 3,571 | 3,335 | 35.1 | 236 | 62.1 | 6.61 [5.82, 7.47] | 135 | 60.5 | 88 | 68.8 | 5.50 [4.25, 6.52] | 13 | 44.8 | 222 | 27 | 57.4 |
Amphetamine Use | 1,156 | 1,045 | 11.0 | 111 | 29.2 | 9.60 [7.96, 11.45] | 62 | 27.8 | 43 | 33.6 | 8.44 [5.78, 10.77] | 6 | 20.7 | 102 | 12 | 25.5 |
Injection Drug Use | 408 | 390 | 4.1 | 18 | 4.7 | 4.41 [2.64, 6.88] | 8 | 3.6 | 10 | 7.8 | 5.37 [2.53, 9.68] | 0 | 0.0 | 16 | 2 | 4.3 |
Syphilis | 312 | 273 | 2.9 | 39 | 10.3 | 12.50 [9.04, 16.69] | 27 | 12.1 | 8 | 6.3 | 6.03 [2.38, 10.86] | 4 | 13.8 | 33 | 3 | 6.4 |
Gonorrhea | 1,452 | 1,358 | 14.3 | 94 | 24.7 | 6.47 [5.26, 7.86] | 52 | 23.3 | 33 | 25.8 | 5.06 [3.36, 6.86] | 9 | 31.0 | 85 | 13 | 27.7 |
Chlamydia | 933 | 892 | 9.4 | 41 | 10.8 | 4.39 [3.20, 4.82] | 20 | 9.0 | 18 | 14.1 | 4.24 [2.46, 6.55] | 3 | 10.3 | 40 | 6 | 12.8 |
Denominators:
HIV-Negative.
All HIV Infection.
All Testers.
Long-Term Infection.
Recent Infection.
Acute Infection.
Drug-Resistant Cases.
Prevalence of HIV-1 transmitted drug resistance was 13.0% overall during the three year period. A total of 47 drug-resistant cases were identified, 77% of which were detected in MSM.
2004 | 2005 | 2006 | ||||
n | % | n | % | n | % | |
|
15 | 100 | 15 | 100 | 17 | 100 |
|
5 | 33.3 | 4 | 26.7 | 5 | 29.4 |
|
11 | 73.3 | 8 | 53.3 | 9 | 52.9 |
|
3 | 20.0 | 3 | 20.0 | 8 | 47.1 |
|
3 | 20.0 | 1 | 6.7 | 1 | 5.9 |
|
0 | 0.0 | 0 | 0.0 | 2 | 11.8 |
NRTI = nucleoside reverse transcriptase inhibitors.
NNRTI = non-nucleoside reverse transcriptase inhibitors.
PI = protease inhibitors.
The characteristics of HIV cases are presented in
There were no significant temporal trends among all testers in the prevalence of HIV infection (p = 0.74), acute infection (p = 0.80), and HIV incidence (p = 0.66), as shown in
Prevalence of HIV-1 transmitted drug resistance did not decrease over the three year period among all testers (p = 0.36) and MSM (p = 0.39), as shown in
Predictors of elevated risk for recent infection for all testers included male gender (AOR = 5.86 [95% CI: 1.84, 18.62]; p = 0.003), amphetamine use (AOR = 2.50 [95% CI: 1.70, 3.69]; p<0.001), sex with a known HIV-positive partner (AOR = 2.12 [95% CI: 1.47, 3.06]; p<0.001), UAI (AOR = 2.01 [95% CI: 1.40, 2.92]; p<0.001), African-American race/ethnicity (AOR = 1.88 [95% CI: 1.16, 3.05]; p = 0.01), and history of gonorrhea (AOR = 1.45 [95% CI: 0.97, 2.19]; p = 0.07). Asian/Pacific Islander race/ethnicity was protective for recent infection (AOR = 0.40 [95% CI: 0.17, 0.91]; p = 0.02). There were no significant correlates of acute infection or drug resistance.
Separate analyses were conducted for MSM, a risk group that accounted for 86.3% of HIV infection cases diagnosed. When analyses were restricted to MSM, recent infection was associated with amphetamine use (AOR = 2.67; p<0.0001), UAI (AOR = 2.27; p = 0.0002), sex with a known HIV-infected partner (AOR = 1.64; p = 0.02), and history of gonorrhea (AOR = 1.62; p = 0.03). Asian/Pacific Islander race/ethnicity (AOR = 0.41; p = 0.03) was associated with a lower risk for recent infection, while sex with an HIV-infected partner (AOR = 0.38; p = 0.03) was associated with a lower risk for drug resistance. Bivariate and multivariate risk models for MSM are detailed in
Predictors of Risk | Recent HIV Infection | Acute HIV Infection | HIV-1 Drug Resistance | |||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||
Year | 0.84 | 0.67, 1.05 | 0.13 | 0.89 | 0.53, 1.49 | 0.65 | 0.98 | 0.65, 1.49 | 0.93 | |||||||||
Age (10 year increase) | 0.93 | 0.76, 1.12 | 0.44 | 1.04 | 0.64, 1.69 | 0.88 | 1.08 | 0.73, 1.59 | 0.71 | |||||||||
|
||||||||||||||||||
White | Reference | Reference | Reference | |||||||||||||||
Latino | 1.33 | 0.85, 2.07 | .011 | 1.30 | 0.48, 3.50 | 0.60 | 0.97 | 0.41, 2.30 | 0.95 | |||||||||
African-American | 1.67 | 0.89, 3.12 | 0.21 | 1.14 | 0.30, 4.35 | 0.84 | 1.15 | 0.37, 3.12 | 0.80 | |||||||||
Asian/Pacific Islander | 0.44 | 0.19, 1.03 | 0.06 | 0.41 | 0.18, 0.93 | 0.03 | 0.57 | 0.70, 4.67 | 0.60 | 1.07 | 0.29, 3.98 | 0.92 | ||||||
Other/Mixed | 1.52 | 0.54, 4.21 | 0.43 | -- | -- | -- | 0.65 | 0.08, 5.33 | 0.68 | |||||||||
|
||||||||||||||||||
Unprotected Anal Intercourse | 3.15 | 2.01, 4.93 | <0.0001 | 2.27 | 1.47, 3.52 | <0.001 | 0.42 | 0.17, 1.03 | 0.06 | 1.67 | 0.91, 3.05 | 0.10 | ||||||
Sex with Known HIV+ Partner | 2.40 | 1.62, 3.52 | <0.0001 | 1.64 | 1.10, 2.47 | 0.02 | 1.02 | 0.41, 2.52 | 0.96 | 0.49 | 0.21, 1.12 | 0.09 | 0.38 | 0.16, 0.91 | 0.03 | |||
Amphetamine Use | 3.90 | 2.60, 5.80 | <0.0001 | 2.67 | 1.77, 4.04 | <0.001 | 0.73 | 0.28, 1.94 | 0.52 | 0.55 | 0.24, 1.27 | 0.16 | ||||||
Injection Drug Use | 2.41 | 1.16, 5.02 | 0.02 | -- | -- | -- | 0.58 | 0.07, 4.61 | 0.61 | |||||||||
Gonorrhea | 2.05 | 1.36, 3.10 | 0.0007 | 1.62 | 1.06, 2.47 | 0.03 | 1.86 | 0.76, 4.55 | 0.17 | 2.26 | 0.89, 5.73 | 0.08 | 1.61 | 0.77, 3.37 | 0.21 | 2.17 | 0.99, 4.77 | 0.05 |
Chlamydia | 1.71 | 1.03, 2.86 | 0.04 | 0.99 | 0.28, 3.50 | 0.98 | 1.31 | 0.56, 3.39 | 0.58 | |||||||||
Syphilis | 1.54 | 0.67, 3.55 | 0.31 | 1.86 | 0.59, 5.88 | 0.29 | 0.71 | 0.21, 2.47 | 0.59 |
OR = Odds Ratio.
AOR = Adjusted Odds Ratio.
CI = Confidence Intervals.
P = P-value.
New HIV diagnoses, recent infections, acute infections, and transmitted drug resistance prevalence remained stable between 2004 and 2006. Slightly more than half of newly-diagnosed HIV cases were long-term infections, one-third were recent infections and close to one-tenth were acute infections. Nearly all acute and recent infection cases were detected in MSM. This result is most likely a reflection of high levels of repeat HIV testing in this population. A recent survey found 97% of MSM in San Francisco had ever tested and 34% had tested in the last 6 months
Prevalence of transmitted HIV-1 drug resistance did not decrease over the three years studied. The majority of drug-resistant cases were detected in MSM and more than one-third of the cases reported having an STI within the past two years. In 85% of the resistant cases, resistance was limited to a single drug class. Resistance to NNRTI was the most common pattern observed, comprising more than half of the cases. The high proportion of cases with resistance to NNRTI is comparable to the national pattern reported by the U.S. Centers for Disease Control and Prevention
The results from this study may not be generalizable to other STI clinics. The patient population characteristics may differ at other clinics, as MSM comprise a large percentage of testers at the San Francisco municipal STI clinic. However, the testing algorithm presented here can be implemented by clinics and public health departments to enhance HIV surveillance programs. The strategy of screening for acute HIV infections at STD clinics has been implemented in a number of U.S. cities. The proportion of acute infections detected in our study (7.6%) was comparable to the findings from STD clinics in New York City (8.6%) and higher than in Baltimore (1.3%)
Our study illustrates how the integration of HIV-1 drug resistance testing with recent and acute infection screening can inform existing HIV/STI surveillance and prevention efforts. Knowledge of transmitted drug resistance prevalence and correlates of acute and recent infections can help target care and prevention strategies. Monitoring HIV-1 drug resistance prevalence in STI patients may be helpful for determining appropriate treatment and post-exposure prophylaxis regimens that are active against viruses circulating in the community.